Contributing editor Ryan Irvine joins us this week with a detailed review of some of his previous recommendations. Ryan is the CEO of KeyStone Financial and one of the country's top experts in small cap stocks.
Background: Merus Labs is a specialty pharmaceutical company focused on acquiring established products. The company leverages its expertise in European and North American markets to optimize the value of underdeveloped pharmaceutical assets.
In reviewing the company's first-quarter performance, Collard said Cornerstone eliminated its primary care product line with the March sale of Factive to Merus Labs International Inc., of Toronto, and Spectracef (cefditoren pivoxil) to Vansen Pharma Inc.